APA (7th ed.) Citation

Piedbois, P., Kosta, S., Montestruc, F., Buyse, M., Salvaggio, S., Cappuzzo, F., . . . Besse, B. (2025). 2032eP Net treatment benefit in ARTEMIA trial comparing OSE2101 to docetaxel in patient with non-small cell lung cancer (NSCLC): Outcomes prioritization based on investigators preferences. Annals of Oncology, 36, S1154. https://doi.org/10.1016/j.annonc.2025.08.2654

Chicago Style (17th ed.) Citation

Piedbois, P., et al. "2032eP Net Treatment Benefit in ARTEMIA Trial Comparing OSE2101 to Docetaxel in Patient with Non-small Cell Lung Cancer (NSCLC): Outcomes Prioritization Based on Investigators Preferences." Annals of Oncology 36 (2025): S1154. https://doi.org/10.1016/j.annonc.2025.08.2654.

MLA (9th ed.) Citation

Piedbois, P., et al. "2032eP Net Treatment Benefit in ARTEMIA Trial Comparing OSE2101 to Docetaxel in Patient with Non-small Cell Lung Cancer (NSCLC): Outcomes Prioritization Based on Investigators Preferences." Annals of Oncology, vol. 36, 2025, p. S1154, https://doi.org/10.1016/j.annonc.2025.08.2654.